

Arthur Kavanaugh

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/929593/publications.pdf>

Version: 2024-02-01

231
papers

18,390
citations

26610

56
h-index

13365

130
g-index

235
all docs

235
docs citations

235
times ranked

12714
citing authors

#	ARTICLE	IF	CITATIONS
1	2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. <i>Arthritis and Rheumatology</i> , 2016, 68, 1-26.	2.9	1,880
2	Rheumatoid arthritis. <i>Nature Reviews Disease Primers</i> , 2018, 4, 18001.	18.1	1,441
3	Group for Research and Assessment of Psoriasis and Psoriatic Arthritis 2015 Treatment Recommendations for Psoriatic Arthritis. <i>Arthritis and Rheumatology</i> , 2016, 68, 1060-1071.	2.9	726
4	Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet</i> , The, 2015, 386, 1137-1146.	6.3	722
5	Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial. <i>Lancet</i> , The, 2013, 382, 780-789.	6.3	688
6	Secukinumab Inhibition of Interleukin-17A in Patients with Psoriatic Arthritis. <i>New England Journal of Medicine</i> , 2015, 373, 1329-1339.	13.9	629
7	Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: Results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT). <i>Arthritis and Rheumatism</i> , 2005, 52, 1227-1236.	6.7	583
8	Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phase 3, multicentre, double-blind, placebo-controlled, randomised PSUMMIT 2 trial. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 990-999.	0.5	576
9	Golimumab, a new human tumor necrosis factor β antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: Twenty-four-week efficacy and safety results of a randomized, placebo-controlled study. <i>Arthritis and Rheumatism</i> , 2009, 60, 976-986.	6.7	547
10	Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trial. <i>Lancet</i> , The, 2009, 373, 633-640.	6.3	545
11	Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics. <i>Journal of the American Academy of Dermatology</i> , 2019, 80, 1029-1072.	0.6	542
12	Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 3-17.	0.5	484
13	Patient perspectives in the management of psoriasis: Results from the population-based Multinational Assessment of Psoriasis and Psoriatic Arthritis Survey. <i>Journal of the American Academy of Dermatology</i> , 2014, 70, 871-881.e30.	0.6	423
14	Treating spondyloarthritis, including ankylosing spondylitis and psoriatic arthritis, to target: recommendations of an international task force. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 6-16.	0.5	397
15	Treatment of psoriatic arthritis in a phase 3 randomised, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 1020-1026.	0.5	372
16	Application of the DAREA/DAPSA score for assessment of disease activity in psoriatic arthritis. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 1441-1447.	0.5	274
17	Ustekinumab, an anti-IL-12/23 p40 monoclonal antibody, inhibits radiographic progression in patients with active psoriatic arthritis: results of an integrated analysis of radiographic data from the phase 3, multicentre, randomised, double-blind, placebo-controlled PSUMMIT-1 and PSUMMIT-2 trials. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 1000-1006.	0.5	255
18	Treat to Target: A Proposed New Paradigm for the Management of Crohn's Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2015, 13, 1042-1050.e2.	2.4	240

#	ARTICLE	IF	CITATIONS
19	Adjustment of therapy in rheumatoid arthritis on the basis of achievement of stable low disease activity with adalimumab plus methotrexate or methotrexate alone: the randomised controlled OPTIMA trial. <i>Lancet, The</i> , 2014, 383, 321-332.	6.3	232
20	Interleukin-17A: a unique pathway in immune-mediated diseases: psoriasis, psoriatic arthritis and rheumatoid arthritis. <i>Immunology</i> , 2014, 141, 133-142.	2.0	200
21	Clinical, functional and radiographic consequences of achieving stable low disease activity and remission with adalimumab plus methotrexate or methotrexate alone in early rheumatoid arthritis: 26-week results from the randomised, controlled OPTIMA study. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 64-71.	0.5	183
22	Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA): updated treatment recommendations for psoriatic arthritis 2021. <i>Nature Reviews Rheumatology</i> , 2022, 18, 465-479.	3.5	182
23	Secukinumab versus adalimumab for treatment of active psoriatic arthritis (EXCEED): a double-blind, parallel-group, randomised, active-controlled, phase 3b trial. <i>Lancet, The</i> , 2020, 395, 1496-1505.	6.3	178
24	US Perspectives in the Management of Psoriasis and Psoriatic Arthritis: Patient and Physician Results from the Population-Based Multinational Assessment of Psoriasis and Psoriatic Arthritis (MAPP) Survey. <i>American Journal of Clinical Dermatology</i> , 2016, 17, 87-97.	3.3	173
25	Golimumab in psoriatic arthritis: One-year clinical efficacy, radiographic, and safety results from a phase III, randomized, placebo-controlled trial. <i>Arthritis and Rheumatism</i> , 2012, 64, 2504-2517.	6.7	171
26	Psoriatic Arthritis and Burden of Disease: Patient Perspectives from the Population-Based Multinational Assessment of Psoriasis and Psoriatic Arthritis (MAPP) Survey. <i>Rheumatology and Therapy</i> , 2016, 3, 91-102.	1.1	146
27	Efficacy and safety of ustekinumab in psoriatic arthritis patients with peripheral arthritis and physician-reported spondylitis: post-hoc analyses from two phase III, multicentre, double-blind, placebo-controlled studies (PSUMMIT-1/PSUMMIT-2). <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 1984-1988.	0.5	131
28	Longterm (52-week) Results of a Phase III Randomized, Controlled Trial of Apremilast in Patients with Psoriatic Arthritis. <i>Journal of Rheumatology</i> , 2015, 42, 479-488.	1.0	122
29	Bimekizumab in patients with active psoriatic arthritis: results from a 48-week, randomised, double-blind, placebo-controlled, dose-ranging phase 2b trial. <i>Lancet, The</i> , 2020, 395, 427-440.	6.3	122
30	Estimating the cost-effectiveness of 54 weeks of infliximab for rheumatoid arthritis. <i>American Journal of Medicine</i> , 2002, 113, 400-408.	0.6	114
31	Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2012: Table A1. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, ii2-ii34.	0.5	114
32	Psoriatic arthritis. <i>Nature Reviews Disease Primers</i> , 2021, 7, 59.	18.1	113
33	Clinical efficacy, radiographic and safety findings through 5+ years of subcutaneous golimumab treatment in patients with active psoriatic arthritis: results from a long-term extension of a randomised, placebo-controlled trial (the GO-REVEAL study). <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 1689-1694.	0.5	112
34	The modified Nail Psoriasis Severity Index: validation of an instrument to assess psoriatic nail involvement in patients with psoriatic arthritis. <i>Journal of Rheumatology</i> , 2007, 34, 123-9.	1.0	105
35	Two-year efficacy and safety of infliximab treatment in patients with active psoriatic arthritis: findings of the Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT). <i>Journal of Rheumatology</i> , 2008, 35, 869-76.	1.0	102
36	Alterations in immune function with biologic therapies for autoimmune disease. <i>Journal of Allergy and Clinical Immunology</i> , 2016, 137, 19-27.	1.5	101

#	ARTICLE	IF	CITATIONS
37	Infantile Hemangiomas: An Updated Review on Risk Factors, Pathogenesis, and Treatment. <i>Birth Defects Research</i> , 2017, 109, 809-815.	0.8	101
38	Influence of Axial Involvement on Clinical Characteristics of Psoriatic Arthritis: Analysis from the Corrona Psoriatic Arthritis/Spondyloarthritis Registry. <i>Journal of Rheumatology</i> , 2018, 45, 1389-1396.	1.0	100
39	A Comparison of Disease Burden in Rheumatoid Arthritis, Psoriatic Arthritis and Axial Spondyloarthritis. <i>PLoS ONE</i> , 2015, 10, e0123582.	1.1	94
40	Clinical Characteristics, Disease Activity, and Patient-Reported Outcomes in Psoriatic Arthritis Patients With Dactylitis or Enthesitis: Results From the Corrona Psoriatic Arthritis/Spondyloarthritis Registry. <i>Arthritis Care and Research</i> , 2017, 69, 1692-1699.	1.5	91
41	Safety and Efficacy of Intravenous Golimumab in Patients With Active Psoriatic Arthritis. <i>Arthritis and Rheumatology</i> , 2017, 69, 2151-2161.	2.9	90
42	Postapproval Comparative Safety Study of Tofacitinib and Biological Disease-Modifying Antirheumatic Drugs: 5-Year Results from a United States-Based Rheumatoid Arthritis Registry. <i>ACR Open Rheumatology</i> , 2021, 3, 173-184.	0.9	88
43	Maintenance of Clinical Efficacy and Radiographic Benefit Through Two Years of Ustekinumab Therapy in Patients With Active Psoriatic Arthritis: Results From a Randomized, Placebo-Controlled Phase III Trial. <i>Arthritis Care and Research</i> , 2015, 67, 1739-1749.	1.5	87
44	Effect of certolizumab pegol with methotrexate on home and work place productivity and social activities in patients with active rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 2009, 61, 1592-1600.	6.7	78
45	Rapid and sustained improvements in health-related quality of life, fatigue, and other patient-reported outcomes in rheumatoid arthritis patients treated with certolizumab pegol plus methotrexate over 1 year: results from the RAPID 1 randomized controlled trial. <i>Arthritis Research and Therapy</i> , 2009, 11, R170.	1.6	78
46	Clinical efficacy, radiographic and safety findings through 2+ years of golimumab treatment in patients with active psoriatic arthritis: results from a long-term extension of the randomised, placebo-controlled GO-REVEAL study. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 1777-1785.	0.5	77
47	Efficacy of Subcutaneous Secukinumab in Patients with Active Psoriatic Arthritis Stratified by Prior Tumor Necrosis Factor Inhibitor Use: Results from the Randomized Placebo-controlled FUTURE 2 Study. <i>Journal of Rheumatology</i> , 2016, 43, 1713-1717.	1.0	77
48	Golimumab 3-year safety update: an analysis of pooled data from the long-term extensions of randomised, double-blind, placebo-controlled trials conducted in patients with rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 538-546.	0.5	75
49	International spondyloarthritis interobserver reliability exercise--the INSPIRE study: II. Assessment of peripheral joints, enthesitis, and dactylitis. <i>Journal of Rheumatology</i> , 2007, 34, 1740-5.	1.0	74
50	Qualifying Unmet Needs and Improving Standards of Care in Psoriatic Arthritis. <i>Arthritis Care and Research</i> , 2014, 66, 1759-1766.	1.5	73
51	Secukinumab for Long-Term Treatment of Psoriatic Arthritis: A Two-Year Followup From a Phase III, Randomized, Double-Blind Placebo-Controlled Study. <i>Arthritis Care and Research</i> , 2017, 69, 347-355.	1.5	72
52	Management of psoriatic arthritis in 2016: a comparison of EULAR and GRAPPA recommendations. <i>Nature Reviews Rheumatology</i> , 2016, 12, 743-750.	3.5	71
53	Benefits and risks of low-dose glucocorticoid treatment in the patient with rheumatoid arthritis. <i>Rheumatology</i> , 2014, 53, 1742-1751.	0.9	69
54	Radiographic Progression of Patients With Psoriatic Arthritis Who Achieve Minimal Disease Activity in Response to Golimumab Therapy: Results Through 5 Years of a Randomized, Placebo-Controlled Study. <i>Arthritis Care and Research</i> , 2016, 68, 267-274.	1.5	69

#	ARTICLE	IF	CITATIONS
55	On the HUNT for cardiovascular risk factors and disease in patients with psoriatic arthritis: population-based data from the Nord-Trøndelag Health Study. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 819-824.	0.5	61
56	A Phase III, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study of 2 Dosing Regimens of Fostamatinib in Patients with Rheumatoid Arthritis with an Inadequate Response to a Tumor Necrosis Factor- α Antagonist. <i>Journal of Rheumatology</i> , 2014, 41, 2120-2128.	1.0	57
57	Comparison of Composite Measures of Disease Activity in Psoriatic Arthritis Using Data From an Interventional Study With Golimumab. <i>Arthritis Care and Research</i> , 2014, 66, 749-756.	1.5	56
58	Psoriatic arthritis: current therapy and future approaches. <i>Rheumatology</i> , 2015, 54, 20-28.	0.9	56
59	Secukinumab in the treatment of psoriatic arthritis: efficacy and safety results through 3 years from the year 1 extension of the randomised phase III FUTURE 1 trial. <i>RMD Open</i> , 2018, 4, e000723.	1.8	56
60	Long-term experience with apremilast in patients with psoriatic arthritis: 5-year results from a PALACE 1â€³3 pooled analysis. <i>Arthritis Research and Therapy</i> , 2019, 21, 118.	1.6	55
61	Adverse reactions to biologic agents: Focus on autoimmune disease therapies. <i>Journal of Allergy and Clinical Immunology</i> , 2005, 116, 900-905.	1.5	54
62	Outcome measures in psoriatic arthritis. <i>Current Rheumatology Reports</i> , 2005, 7, 195-200.	2.1	51
63	Tumor necrosis factor as a therapeutic target of rheumatologic disease. <i>Expert Opinion on Therapeutic Targets</i> , 2007, 11, 1369-1384.	1.5	51
64	Effect of ustekinumab on physical function and health-related quality of life in patients with psoriatic arthritis: a randomized, placebo-controlled, phase II trial. <i>Current Medical Research and Opinion</i> , 2010, 26, 2385-2392.	0.9	51
65	Markers of inflammation and bone remodelling associated with improvement in clinical response measures in psoriatic arthritis patients treated with golimumab. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 83-88.	0.5	51
66	Pro- and anti-inflammatory eicosanoids in psoriatic arthritis. <i>Metabolomics</i> , 2019, 15, 65.	1.4	49
67	Psoriatic arthritis: latest treatments and their place in therapy. <i>Therapeutic Advances in Chronic Disease</i> , 2015, 6, 194-203.	1.1	48
68	Patientâ€Reported Outcomes and the Association With Clinical Response in Patients With Active Psoriatic Arthritis Treated With Golimumab: Findings Through 2 Years of a Phase III, Multicenter, Randomized, Doubleâ€Blind, Placeboâ€Controlled Trial. <i>Arthritis Care and Research</i> , 2013, 65, 1666-1673.	1.5	44
69	Economic consequences of established rheumatoid arthritis and its treatment. <i>Best Practice and Research in Clinical Rheumatology</i> , 2007, 21, 929-942.	1.4	43
70	Functional status and radiographic joint damage are associated with health economic outcomes in patients with rheumatoid arthritis. <i>Journal of Rheumatology</i> , 2004, 31, 849-55.	1.0	42
71	Ultrasonographic evaluation in psoriatic arthritis is of major importance in evaluating disease activity. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 2108-2113.	0.5	40
72	The impact of infliximab treatment on quality of life in patients with inflammatory rheumatic diseases. <i>Arthritis Research and Therapy</i> , 2007, 9, R103.	1.6	39

#	ARTICLE	IF	CITATIONS
73	Patient-reported outcomes in rheumatoid arthritis. <i>Current Opinion in Rheumatology</i> , 2012, 24, 327-334.	2.0	39
74	Secukinumab Provides Sustained Improvements in the Signs and Symptoms of Psoriatic Arthritis: Final 5-year Results from the Phase 3 FUTURE 1 Study. <i>ACR Open Rheumatology</i> , 2020, 2, 18-25.	0.9	39
75	Effect of infliximab therapy on employment, time lost from work, and productivity in patients with psoriatic arthritis. <i>Journal of Rheumatology</i> , 2006, 33, 2254-9.	1.0	39
76	Treatment of Psoriatic Arthritis with Tumor Necrosis Factor Inhibitors: Longer-term Outcomes Including Enthesitis and Dactylitis with Golimumab Treatment in the Longterm Extension of a Randomized, Placebo-controlled Study (GO-REVEAL). <i>Journal of rheumatology Supplement, The</i> , 2012, 89, 90-93.	2.2	38
77	Systematic Review of Treatments for Psoriatic Arthritis: 2014 Update for the GRAPPA. <i>Journal of Rheumatology</i> , 2014, 41, 2273-2276.	1.0	37
78	Bedside to bench: defining the immunopathogenesis of psoriatic arthritis. <i>Nature Reviews Rheumatology</i> , 2019, 15, 645-656.	3.5	37
79	Radiographic Progression According to Baseline C-reactive Protein Levels and Other Risk Factors in Psoriatic Arthritis Treated with Tofacitinib or Adalimumab. <i>Journal of Rheumatology</i> , 2019, 46, 1089-1096.	1.0	37
80	The evolving use of tumor necrosis factor inhibitors in rheumatoid arthritis. <i>Journal of Rheumatology</i> , 2004, 31, 1881-4.	1.0	37
81	Rheumatoid arthritis in dermatology. <i>Clinics in Dermatology</i> , 2006, 24, 430-437.	0.8	36
82	Comparison of employability outcomes among patients with early or long-standing rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 2008, 59, 510-514.	6.7	36
83	New GRAPPA and EULAR recommendations for the management of psoriatic arthritis. <i>Rheumatology</i> , 2017, 56, kew390.	0.9	36
84	Serum metabolomic profiling predicts synovial gene expression in rheumatoid arthritis. <i>Arthritis Research and Therapy</i> , 2018, 20, 164.	1.6	36
85	Update on anti-tumor necrosis factor therapy in the spondyloarthropathies including psoriatic arthritis. <i>Current Opinion in Rheumatology</i> , 2006, 18, 347-353.	2.0	35
86	Anakinra (Interleukin-1 Receptor Antagonist) has positive effects on function and quality of life in patients with rheumatoid arthritis. <i>Advances in Therapy</i> , 2006, 23, 208-217.	1.3	34
87	Comprehensive disease control (CDC): what does achieving CDC mean for patients with rheumatoid arthritis?. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 2165-2174.	0.5	33
88	Three-dimensional ultrashort echo time cones (3D UTE-Cones) magnetic resonance imaging of entheses and tendons. <i>Magnetic Resonance Imaging</i> , 2018, 49, 4-9.	1.0	33
89	Achilles enthesitis defined by ultrasound is not associated with clinical enthesitis in patients with psoriatic arthritis. <i>RMD Open</i> , 2017, 3, e000486.	1.8	32
90	Economic Burden of Psoriatic Arthritis. <i>Pharmacoeconomics</i> , 2008, 26, 121-129.	1.7	31

#	ARTICLE	IF	CITATIONS
91	Predicting low disease activity and remission using early treatment response to antitumour necrosis factor therapy in patients with rheumatoid arthritis: exploratory analyses from the TEMPO trial. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 206-212.	0.5	31
92	Metabolomic profiling predicts outcome of rituximab therapy in rheumatoid arthritis. <i>RMD Open</i> , 2016, 2, e000289.	1.8	31
93	Therapeutic benefit of apremilast on enthesitis and dactylitis in patients with psoriatic arthritis: a pooled analysis of the PALACE 1-3 studies. <i>RMD Open</i> , 2018, 4, e000669.	1.8	31
94	Predictors of Achieving Remission among Patients with Psoriatic Arthritis Initiating a Tumor Necrosis Factor Inhibitor. <i>Journal of Rheumatology</i> , 2019, 46, 475-482.	1.0	31
95	Psoriatic arthritis: exploring the occurrence of sleep disturbances, fatigue, and depression and their correlates. <i>Arthritis Research and Therapy</i> , 2020, 22, 198.	1.6	31
96	Value of the Routine Assessment of Patient Index Data 3 in Patients With Psoriatic Arthritis: Results From a Tight-Control Clinical Trial and an Observational Cohort. <i>Arthritis Care and Research</i> , 2018, 70, 1198-1205.	1.5	29
97	The contribution of joint and skin improvements to the health-related quality of life of patients with psoriatic arthritis: a post hoc analysis of two randomised controlled studies. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 1215-1219.	0.5	29
98	Assessing structural damage progression in psoriatic arthritis and its role as an outcome in research. <i>Arthritis Research and Therapy</i> , 2020, 22, 18.	1.6	29
99	Safety and Efficacy of Filgotinib: Up to 4-year Results From an Open-label Extension Study of Phase II Rheumatoid Arthritis Programs. <i>Journal of Rheumatology</i> , 2021, 48, 1230-1238.	1.0	29
100	The effect of golimumab on haemoglobin levels in patients with rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis. <i>Rheumatology</i> , 2013, 52, 1845-1855.	0.9	28
101	Efficacy, safety and immunogenicity of GP2015, an etanercept biosimilar, compared with the reference etanercept in patients with moderate-to-severe rheumatoid arthritis: 24-week results from the comparative phase III, randomised, double-blind EQUIRA study. <i>RMD Open</i> , 2018, 4, e000757.	1.8	28
102	Patient-derived Joint Counts Are a Potential Alternative for Determining Disease Activity Score. <i>Journal of Rheumatology</i> , 2010, 37, 1035-1041.	1.0	25
103	Treatments for Nail Psoriasis: A Systematic Review by the GRAPPA Nail Psoriasis Work Group. <i>Journal of Rheumatology</i> , 2014, 41, 2306-2314.	1.0	25
104	Frequency, distribution and immunologic nature of infusion reactions in subjects receiving pegloticase for chronic refractory gout. <i>Arthritis Research and Therapy</i> , 2017, 19, 191.	1.6	25
105	Prediction and benefits of minimal disease activity in patients with psoriatic arthritis and active skin disease in the ADEPT trial. <i>RMD Open</i> , 2017, 3, e000415.	1.8	24
106	Information technology in rheumatology. <i>Clinical and Experimental Rheumatology</i> , 2016, 34, 1.	0.4	24
107	Predictors of disease activity and structural progression after treatment with adalimumab plus methotrexate or continued methotrexate monotherapy in patients with early rheumatoid arthritis and suboptimal response to methotrexate. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 1566-1572.	0.5	23
108	Certolizumab pegol plus methotrexate 5-year results from the rheumatoid arthritis prevention of structural damage (RAPID) 2 randomized controlled trial and long-term extension in rheumatoid arthritis patients. <i>Arthritis Research and Therapy</i> , 2015, 17, 245.	1.6	22

#	ARTICLE	IF	CITATIONS
109	Testing treat-to-target outcomes with initial methotrexate monotherapy compared with initial tumour necrosis factor inhibitor (adalimumab) plus methotrexate in early rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 289-292.	0.5	22
110	Allele and antigen-specific treatment of rheumatoid arthritis: a double blind, placebo controlled phase 1 trial. <i>Journal of Rheumatology</i> , 2003, 30, 449-54.	1.0	22
111	Impact of skin, musculoskeletal and psychosocial aspects on quality of life in psoriatic arthritis patients: A cross-sectional study of outpatient clinic patients in the biologic treatment era. <i>RMD Open</i> , 2020, 6, e001223.	1.8	21
112	Filgotinib, a novel JAK1-preferential inhibitor for the treatment of rheumatoid arthritis: An overview from clinical trials. <i>Modern Rheumatology</i> , 2022, 32, 1-11.	0.9	21
113	Adult Inflammatory Arthritides: What the Radiologist Should Know. <i>Radiographics</i> , 2016, 36, 1849-1870.	1.4	20
114	Clinical and Patient-reported Outcomes in Patients with Psoriatic Arthritis (PsA) by Body Surface Area Affected by Psoriasis: Results from the Corrona PsA/Spondyloarthritis Registry. <i>Journal of Rheumatology</i> , 2017, 44, 1151-1158.	1.0	20
115	Osteoporosis in psoriatic arthritis: a cross-sectional study of an outpatient clinic population. <i>RMD Open</i> , 2018, 4, e000631.	1.8	20
116	Switch from reference etanercept to SDZ ETN, an etanercept biosimilar, does not impact efficacy, safety, and immunogenicity of etanercept in patients with moderate-to-severe rheumatoid arthritis: 48-week results from the phase III, randomized, double-blind EQUIRA study. <i>Arthritis Research and Therapy</i> , 2019, 21, 130.	1.6	19
117	Adiposity and Physical Activity as Risk Factors for Developing Psoriatic Arthritis: Longitudinal Data From a Population-Based Study in Norway. <i>Arthritis Care and Research</i> , 2021, 73, 432-441.	1.5	19
118	Need for Improvement in Current Treatment of Psoriatic Arthritis: Study of an Outpatient Clinic Population. <i>Journal of Rheumatology</i> , 2017, 44, 431-436.	1.0	18
119	CNS Lymphocytic Vasculitis in a Young Woman With COVID-19 Infection. <i>Neurology: Neuroimmunology and Neuroinflammation</i> , 2021, 8, .	3.1	18
120	Economic issues with new rheumatologic therapeutics. <i>Current Opinion in Rheumatology</i> , 2007, 19, 272-276.	2.0	17
121	Effect of high-intensity interval training on cardiovascular disease risk factors and body composition in psoriatic arthritis: a randomised controlled trial. <i>RMD Open</i> , 2018, 4, e000729.	1.8	17
122	Efficacy of ustekinumab in biologic-naïve patients with psoriatic arthritis by prior treatment exposure and disease duration: data from PSUMMIT 1 and PSUMMIT 2. <i>RMD Open</i> , 2019, 5, e000990.	1.8	17
123	Inhibition of IL6 in rheumatoid arthritis and juvenile idiopathic arthritis. <i>Experimental Cell Research</i> , 2011, 317, 1286-1292.	1.2	16
124	A review of disease activity measures for psoriatic arthritis: what is the best approach?. <i>Expert Review of Clinical Immunology</i> , 2014, 10, 1241-1254.	1.3	16
125	Impact of tocilizumab monotherapy on patient-reported outcomes in patients with rheumatoid arthritis from two randomised controlled trials. <i>RMD Open</i> , 2017, 3, e000496.	1.8	16
126	Ten years of follow-up data in psoriatic arthritis: results based on standardized monitoring of patients in an ordinary outpatient clinic in southern Norway. <i>Arthritis Research and Therapy</i> , 2018, 20, 160.	1.6	16

#	ARTICLE	IF	CITATIONS
127	Effect of adalimumab on the work-related outcomes scores in patients with early rheumatoid arthritis receiving methotrexate. <i>Rheumatology</i> , 2016, 55, 1458-1465.	0.9	15
128	Benefit of biologics initiation in moderate versus severe rheumatoid arthritis: evidence from a United States registry. <i>Rheumatology</i> , 2017, 56, 1095-1101.	0.9	15
129	Incidence and Predictors of Biological Antirheumatic Drug Discontinuation Attempts among Patients with Rheumatoid Arthritis in Remission: A CORRONA and Ninja Collaborative Cohort Study. <i>Journal of Rheumatology</i> , 2015, 42, 2238-2246.	1.0	14
130	Advances in use of immunomodulatory agents—a rheumatology perspective. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2015, 12, 363-368.	8.2	14
131	Clinical Remission in Patients with Active Psoriatic Arthritis Treated with Adalimumab and Correlations in Joint and Skin Manifestations. <i>Journal of Rheumatology</i> , 2015, 42, 952-959.	1.0	14
132	Efficacy and Safety of Intravenous Golimumab Through One Year in Patients With Active Psoriatic Arthritis. <i>Arthritis Care and Research</i> , 2020, 72, 806-813.	1.5	14
133	GRAPPA Treatment Recommendations: An Update From the 2020 GRAPPA Annual Meeting. <i>Journal of Rheumatology</i> , 2021, , jrheum.201681.	1.0	14
134	Choline metabolite, trimethylamine N-oxide (TMAO), is associated with inflammation in psoriatic arthritis. <i>Clinical and Experimental Rheumatology</i> , 2019, 37, 481-484.	0.4	14
135	Radiographic Progression in Psoriatic Arthritis Achieving a Good Response to Treatment: Data Using Newer Composite Indices of Disease Activity. <i>Arthritis Care and Research</i> , 2018, 70, 797-800.	1.5	13
136	Long-Term Safety and Tolerability of Apremilast Versus Placebo in Psoriatic Arthritis: A Pooled Safety Analysis of Three Phase III, Randomized, Controlled Trials. <i>ACR Open Rheumatology</i> , 2020, 2, 459-470.	0.9	12
137	Differences in oxylipin profile in psoriasis versus psoriatic arthritis. <i>Arthritis Research and Therapy</i> , 2021, 23, 200.	1.6	12
138	GRAPPA Treatment Recommendations: Updates and Methods. <i>Journal of Rheumatology</i> , 2020, 96, 41-45.	1.0	12
139	GRAPPA Treatment Recommendations: 2021 Update. <i>Journal of Rheumatology</i> , 2022, , jrheum.211331.	1.0	12
140	Potential Impact of Sex and BMI on Response to Therapy in Psoriatic Arthritis: Post Hoc Analysis of Results From the SEAM-PsA Trial. <i>Journal of Rheumatology</i> , 2022, 49, 885-893.	1.0	12
141	Development and initial evaluation of a culturally sensitive cholesterol-lowering diet program for Mexican and African American patients with systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 2000, 13, 205-212.	6.7	11
142	Combination cytokine therapy: The next generation of rheumatoid arthritis therapy?. <i>Arthritis and Rheumatism</i> , 2002, 47, 87-92.	6.7	11
143	Secondary immune deficiencies associated with biological therapeutics. <i>Current Allergy and Asthma Reports</i> , 2003, 3, 389-395.	2.4	11
144	Infection prophylaxis in antirheumatic therapy: emphasis on vaccination. <i>Current Opinion in Rheumatology</i> , 2009, 21, 419-424.	2.0	11

#	ARTICLE	IF	CITATIONS
145	Treatment of Psoriatic Arthritis with Biological Agents. <i>Seminars in Cutaneous Medicine and Surgery</i> , 2010, 29, 56-62.	1.6	11
146	Can we improve the performance and reporting of investigator-initiated clinical trials? Rheumatoid arthritis as an example: Table A1. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 1755-1760.	0.5	11
147	Psoriatic Arthritis: Newer and Older Therapies. <i>Current Rheumatology Reports</i> , 2019, 21, 75.	2.1	11
148	Final 10-year effectiveness and safety results from study DE020: adalimumab treatment in patients with rheumatoid arthritis and an inadequate response to standard therapy. <i>Rheumatology</i> , 2015, 54, kev249.	0.9	10
149	Demography, baseline disease characteristics, and treatment history of psoriasis patients with self-reported psoriatic arthritis enrolled in the PSOLAR registry. <i>BMC Rheumatology</i> , 2018, 2, 29.	0.6	10
150	An overview of low disease activity and remission in psoriatic arthritis. <i>Clinical and Experimental Rheumatology</i> , 2015, 33, S51-4.	0.4	10
151	Adalimumab for the treatment of rheumatoid arthritis. <i>Therapy: Open Access in Clinical Medicine</i> , 2005, 2, 13-21.	0.2	9
152	Novel therapies for rheumatoid arthritis. <i>Pathophysiology</i> , 2005, 12, 217-225.	1.0	9
153	The Pharmacoeconomics of Newer Therapeutics for Rheumatic Diseases. <i>Rheumatic Disease Clinics of North America</i> , 2006, 32, 45-56.	0.8	9
154	The efficacy of ustekinumab on the articular and dermatologic manifestations of psoriatic arthritis. <i>Current Rheumatology Reports</i> , 2009, 11, 233-234.	2.1	9
155	Psoriatic arthritis: current therapy and future directions. <i>Expert Opinion on Pharmacotherapy</i> , 2013, 14, 1755-1764.	0.9	9
156	Bone mineral density in patients with psoriatic arthritis: data from the Nord-Trøndelag Health Study 3. <i>RMD Open</i> , 2017, 3, e000413.	1.8	9
157	Long-Term Radiographic and Patient-Reported Outcomes in Patients with Rheumatoid Arthritis Treated with Tofacitinib: ORAL Start and ORAL Scan Post-hoc Analyses. <i>Rheumatology and Therapy</i> , 2018, 5, 341-353.	1.1	9
158	Baseline patient characteristics associated with response to biologic therapy in patients with psoriatic arthritis enrolled in the Corrona Psoriatic Arthritis/Spondyloarthritis Registry. <i>RMD Open</i> , 2018, 4, e000638.	1.8	9
159	Imbalance Between Omega-6- and Omega-3-Derived Bioactive Lipids in Arthritis in Older Adults. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2021, 76, 415-425.	1.7	9
160	Reading and interpreting economic evaluations in rheumatoid arthritis: an assessment of selected instruments for critical appraisal. <i>Journal of Rheumatology</i> , 2003, 30, 1739-47.	1.0	9
161	Biologic Agents in Rheumatology: Safety Considerations. <i>Rheumatic Disease Clinics of North America</i> , 2006, 32, 3-10.	0.8	8
162	Desirability Scores for Assessing Multiple Outcomes in Systemic Rheumatic Diseases. <i>Communications in Statistics - Theory and Methods</i> , 2009, 38, 3461-3471.	0.6	8

#	ARTICLE	IF	CITATIONS
163	Change in cardiovascular risk factors in patients who develop psoriatic arthritis: longitudinal data from the Nord-Trøndelag Health Study (HUNT). <i>RMD Open</i> , 2018, 4, e000630.	1.8	8
164	Treat to Target in Psoriatic Arthritis. <i>Rheumatic Disease Clinics of North America</i> , 2019, 45, 505-517.	0.8	8
165	Interleukin-6 inhibition and clinical efficacy in rheumatoid arthritis treatment—data from randomized clinical trials. <i>Bulletin of the NYU Hospital for Joint Diseases</i> , 2007, 65 Suppl 1, S16-20.	0.7	8
166	Salivary Gland Ultrasonography as a Diagnostic Tool for Secondary Sjögren Syndrome in Rheumatoid Arthritis. <i>Journal of Rheumatology</i> , 2015, 42, 1119-1122.	1.0	7
167	Certolizumab pegol for the treatment of psoriatic arthritis. <i>Expert Review of Clinical Immunology</i> , 2015, 11, 307-318.	1.3	7
168	Secukinumab for the treatment of psoriatic arthritis. <i>Expert Review of Clinical Immunology</i> , 2016, 12, 1027-1036.	1.3	7
169	The role of golimumab in inflammatory arthritis. A review of the evidence. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2018, 10, 181-194.	1.2	7
170	GRAPPA 2018 Project Report. <i>Journal of Rheumatology</i> , 2019, 95, 54-57.	1.0	7
171	Secukinumab in United States Biologic-Naïve Patients With Psoriatic Arthritis: Results From the Randomized, Placebo-Controlled CHOICE Study. <i>Journal of Rheumatology</i> , 2022, 49, 894-902.	1.0	7
172	Novel Treatment Concepts in Psoriatic Arthritis. <i>Rheumatic Disease Clinics of North America</i> , 2015, 41, 739-754.	0.8	6
173	Risk of infantile hemangiomas in the offspring of women with autoimmune disease and the pathogenic implications of these lesions. <i>American Journal of Medical Genetics, Part A</i> , 2018, 176, 570-577.	0.7	6
174	Radiographic Progression Inhibition with Intravenous Golimumab in Psoriatic Arthritis: Week 24 Results of a Phase III, Randomized, Double-blind, Placebo-controlled Trial. <i>Journal of Rheumatology</i> , 2019, 46, 595-602.	1.0	6
175	OP0108—DUAL NEUTRALISATION OF IL-17A AND IL-17F WITH BIMEKIZUMAB IN PATIENTS WITH ACTIVE PSA: OVERALL AND TNF-INHIBITOR-NAÏVE POPULATION RESULTS FROM A 48-WEEK PHASE 2B RANDOMISED STUDY. , 2019, , .		6
176	Psoriatic arthritis: treat-to-target. <i>Clinical and Experimental Rheumatology</i> , 2012, 30, S123-5.	0.4	6
177	Ixekizumab improves patient-reported outcomes in patients with active psoriatic arthritis and inadequate response to tumour necrosis factor inhibitors: SPIRIT-P2 results to 52 weeks. <i>Clinical and Experimental Rheumatology</i> , 2019, 37, 566-574.	0.4	6
178	Early Real-World Experience of Tofacitinib for Psoriatic Arthritis: Data from a United States Healthcare Claims Database. <i>Advances in Therapy</i> , 2022, 39, 2932-2945.	1.3	6
179	Sex difference in disease burden of inflammatory arthritis patients treated with tumor necrosis factor inhibitors as part of standard care. <i>PLoS ONE</i> , 2022, 17, e0266816.	1.1	6
180	Novel approaches to biological therapy for psoriatic arthritis. <i>Expert Opinion on Biological Therapy</i> , 2016, 16, 173-186.	1.4	5

#	ARTICLE	IF	CITATIONS
181	Achieving comprehensive disease control in patients with early and established rheumatoid arthritis treated with adalimumab plus methotrexate versus methotrexate alone. <i>RMD Open</i> , 2017, 3, e000445.	1.8	5
182	Golimumab in the treatment of psoriatic arthritis. <i>Expert Review of Clinical Immunology</i> , 2018, 14, 893-898.	1.3	5
183	Disease activity and biologic use in patients with psoriatic arthritis or rheumatoid arthritis. <i>Clinical Rheumatology</i> , 2018, 37, 2275-2280.	1.0	5
184	Exposure-Response Relationship of Certolizumab Pegol and Achievement of Low Disease Activity and Remission in Patients With Rheumatoid Arthritis. <i>Clinical and Translational Science</i> , 2020, 13, 743-751.	1.5	5
185	Interleukin-17 inhibition in psoriatic arthritis. <i>Clinical and Experimental Rheumatology</i> , 2015, 33, S119-23.	0.4	5
186	Guidelines for RA therapy-avoiding hamartia. <i>Nature Reviews Rheumatology</i> , 2010, 6, 505-506.	3.5	4
187	Pregnancy: Data, Outcomes, and Treatment Paradigms in Rheumatology. <i>Journal of Rheumatology</i> , 2015, 42, 1357-1358.	1.0	4
188	International Treatment Recommendations Update: A Report from the GRAPPA 2016 Annual Meeting. <i>Journal of Rheumatology</i> , 2017, 44, 684-685.	1.0	4
189	Pooled safety results across phase 3 randomized trials of intravenous golimumab in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. <i>Arthritis Research and Therapy</i> , 2022, 24, 73.	1.6	4
190	Baseline Disease Activity Predicts Achievement of cDAPSA Treatment Targets With Apremilast: Phase III Results in DMARD-naïve Patients With Psoriatic Arthritis. <i>Journal of Rheumatology</i> , 2022, 49, 694-699.	1.0	4
191	Biomarkers in rheumatology: promise and pitfalls. <i>Future Rheumatology</i> , 2008, 3, 303-305.	0.2	3
192	Anti-cytokine Therapies. , 2017, , 999-1019.		3
193	FRI0451-SECUKINUMAB PROVIDES SUSTAINED IMPROVEMENTS IN THE SIGNS AND SYMPTOMS IN PSORIATIC ARTHRITIS: FINAL 5 YEAR EFFICACY AND SAFETY RESULTS FROM A PHASE 3 TRIAL. , 2019, , .		3
194	Effects of Intravenous Golimumab on Health-Related Quality of Life in Patients With Psoriatic Arthritis: 24-Week Results of the GO-VIBRANT Trial. <i>Value in Health</i> , 2020, 23, 1286-1291.	0.1	3
195	Inhibition of radiographic progression across levels of composite index-defined disease activity in patients with active psoriatic arthritis treated with intravenous golimumab: results from a phase-3, double-blind, placebo-controlled trial. <i>Arthritis Research and Therapy</i> , 2020, 22, 43.	1.6	3
196	The effect of intravenous golimumab on health-related quality of life and work productivity in patients with active psoriatic arthritis: results of the Phase 3 GO-VIBRANT trial. <i>Clinical Rheumatology</i> , 2021, 40, 3667-3677.	1.0	3
197	Lipidomic Profiling in Synovial Tissue. <i>Frontiers in Medicine</i> , 2022, 9, 857135.	1.2	3
198	Correspondence on "No efficacy of anti-IL-23 therapy for axial spondyloarthritis in randomised controlled trials but in post-hoc analyses of psoriatic arthritis-related "physician-reported spondylitis"™. <i>Annals of the Rheumatic Diseases</i> , 2023, 82, e187-e187.	0.5	3

#	ARTICLE	IF	CITATIONS
199	Is there a pharmacoeconomic argument supporting the use of tumor necrosis factor inhibitors in early rheumatoid arthritis?. <i>Nature Clinical Practice Rheumatology</i> , 2006, 2, 346-347.	3.2	2
200	Oral Abstracts 7: RA Clinical * O37. Long-Term Outcomes of Early RA Patients Initiated with Adalimumab Plus Methotrexate Compared with Methotrexate Alone Following a Targeted Treatment Approach. <i>Rheumatology</i> , 2013, 52, i44-i55.	0.9	2
201	Patient Perspectives on Psoriasis Management: U.S. Results of the Population-Based Multinational Assessment of Psoriasis and Psoriatic Arthritis Survey. <i>Psoriasis Forum</i> , 2014, 20a, 124-131.	0.1	2
202	Addressing comorbidities in systemic inflammatory disorders. <i>Nature Reviews Rheumatology</i> , 2015, 11, 689-691.	3.5	2
203	GRAPPA 2019 Research Recipient Awards Report. <i>Journal of Rheumatology</i> , 2021, , jrheum.201682.	1.0	2
204	Updates on Psoriasis and Cutaneous Oncology: Proceedings from the 2016 MauiDerm Meeting based on presentations by. <i>Journal of Clinical and Aesthetic Dermatology</i> , 2016, 9, S5-S29.	0.1	2
205	Association between TNFi anti-drug antibodies, smoking, and disease activity in patients with inflammatory arthritis: Results from a Norwegian cross-sectional observational study. <i>Rheumatology and Therapy</i> , 2022, 9, 1171-1179.	1.1	2
206	The treatment of psoriatic arthritis and inflammatory spondylitis. <i>Current Pain and Headache Reports</i> , 2008, 12, 412-417.	1.3	1
207	Guidelines in rheumatology: quo vadis?. <i>Nature Reviews Rheumatology</i> , 2009, 5, 423-424.	3.5	1
208	Do TNF inhibitors influence lymphoma development?. <i>Nature Reviews Rheumatology</i> , 2017, 13, 697-698.	3.5	1
209	258â€¦Secukinumab provides sustained improvements in the signs and symptoms in psoriatic arthritis: final 5-year efficacy and safety results from the FUTURE 1 Phase 3 trial. <i>Rheumatology</i> , 2019, 58, .	0.9	1
210	AB0742â€¦ACHIEVEMENT OF PASDAS LOW DISEASE ACTIVITY AND VERY LOW DISEASE ACTIVITY IN PATIENTS WITH PSORIATIC ARTHRITIS TREATED WITH CERTOLIZUMAB PEGOL OVER 4 YEARS AND THE OVERLAP WITH DAPSA AND MDA DISEASE ACTIVITY TARGETS. , 2019, , .		1
211	FRI0450â€¦PROBABILITY OF ACHIEVING LOW DISEASE ACTIVITY OR REMISSION IN SUBJECTS WITH ACTIVE PSORIATIC ARTHRITIS TREATED WITH APREMILAST. , 2019, , .		1
212	Anti-Citrullinated Protein Antibodies in Patients with Psoriatic Arthritis. <i>Rheumatology</i> , 2021, , .	0.9	1
213	Anticytokine Therapies. , 2013, , 957-977.e4.		1
214	Adalimumab for the treatment of rheumatoid arthritis. <i>Therapy: Open Access in Clinical Medicine</i> , 2005, 2, 13-21.	0.2	1
215	Elderly Onset Rheumatoid Arthritis. , 2011, , 145-150.		1
216	Trial design in psoriatic arthritis: what could be changed?. <i>Clinical and Experimental Rheumatology</i> , 2015, 33, S15-8.	0.4	1

#	ARTICLE	IF	CITATIONS
217	Clinically meaningful improvement in work productivity loss in active psoriatic arthritis: post-hoc analysis of SPIRIT-P1 and SPIRIT-P2 trials. <i>Clinical and Experimental Rheumatology</i> , 2020, 38, 1227-1230.	0.4	1
218	Clinical Controversies in Psoriatic Disease: The Use of IL-17i/IL-23i Versus TNFi as First-line Advanced Therapy in Psoriatic Arthritis. <i>Journal of Rheumatology</i> , 2022, , jrheum .211325.	1.0	1
219	Articular and Extra-Articular Benefits in ACR20 Non-responders at Week 104 Treated With Apremilast: Pooled Analysis of Three Randomized Controlled Trials. <i>Rheumatology and Therapy</i> , 2021, 8, 1677-1691.	1.1	1
220	Implications of radiographic joint damage in rheumatoid arthritis: Comment on the editorial by Weisman. <i>Arthritis and Rheumatism</i> , 2006, 54, 2035-2035.	6.7	0
221	Treatment options for psoriatic arthritis. <i>Expert Opinion on Orphan Drugs</i> , 2014, 2, 695-708.	0.5	0
222	How can the key findings from the GO-REVEAL study be translated to the clinic?. <i>International Journal of Clinical Rheumatology</i> , 2015, 10, 441-449.	0.3	0
223	195â€¦Secukinumab Significantly Improves the Signs and Symptoms of Active Psoriatic Arthritis in Patients Previously Exposed to Anti-Tumour Necrosis Factor Therapy and Anti-Tumour Necrosis Factor-Naive Patients: 52 Week Results from the Phase III Future 2 Trial. <i>Rheumatology</i> , 0, , .	0.9	0
224	069.â€¦CONSTRUCT VALIDITY, RESPONSIVENESS AND MINIMALLY IMPORTANT DIFFERENCE OF THE ROUTINE ASSESSMENT OF PATIENT INDEX DATA 3 IN PSORIATIC ARTHRITIS. <i>Rheumatology</i> , 2017, 56, .	0.9	0
225	171â€¦Secukinumab provides sustained PASDAS related low disease activity in psoriatic arthritis: two year results from the FUTURE 2 study. <i>Rheumatology</i> , 2018, 57, .	0.9	0
226	166â€¦Long-term (156-week) improvements in dactylitis and enthesitis with apremilast in psoriatic arthritis subjects: analysis of a large, pooled PALACE 1-3 database. <i>Rheumatology</i> , 2018, 57, .	0.9	0
227	THU0044â€¦PRO- AND ANTI-INFLAMMATORY MEDIATORS OF SYSTEMIC INFLAMMATION AND ARTHRITIS IN THE ELDERLY. , 2019, , .		0
228	P261â€¦Continuing versus withdrawing ixekizumab in patients with PsA who achieved sustained minimal disease activity: results from the SPIRIT-P3 study. <i>Rheumatology</i> , 2020, 59, .	0.9	0
229	Adalimumab in ankylosing spondylitis: an evidence-based review of its place in therapy. <i>Core Evidence</i> , 2008, 2, 295-305.	4.7	0
230	Autoimmune consequences of biologics. <i>Journal of Allergy and Clinical Immunology</i> , 2022, 149, 48-50.	1.5	0
231	2021 GRAPPA Meet the Experts Session: A Summary of Presentations.. <i>Journal of Rheumatology</i> , 2022, , .	1.0	0